Treating all U.S. patients infected with hepatitis B virus (HBV) would significantly decrease disease burden and slash the cost of treating the infection nationwide, according to data that modeled care through the next three decades.
Furthermore, if programs are put in place to decrease the annual price of HBV care, the strategy could become highly cost-effective, or even result in cost savings, the investigators reported.
According to modeling conducted for the study, there were